Global AMR R&D Hub

The Global Antimicrobial Resistance Research and Development Hub, or Global AMR R&D Hub for short, is an initiative of international R&D funders to help combat antimicrobial drug resistance. 

The hub officially launched during the 2018 World Health Assembly, one year after G20 leaders decided to strengthen global cooperation against resistant germs.

The hub's goal is to identify key research and development tasks and provide information to support funding distribution decisions. Members will continue to make their funding decisions independently. However, all stakeholders involved will coordinate their research activities with each other. This approach should optimize resource allocation and encourage collaborative projects, such as developing new diagnostic measures and active compounds against resistant pathogens unaffected by common antibiotics. These substances are urgently needed, but developing new drugs is tedious and costly, offering little incentive for the pharmaceutical industry. Consequently, public research funding is important and must be promoted for the benefit of patients.

Nineteen government and non-governmental organizations are currently active in the Global AMR R&D Hub, including Russia, China, the United States, France, the Bill & Melinda Gates Foundation, Wellcome, and the European Commission. The Federal Ministry of Education and Research (BMBF) (since 2025: Federal Ministry of Research, Technology and Space (BMFTR)) was instrumental in setting up the hub. The secretariat is based in Berlin, under the umbrella of the DZIF.